Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   42564   clinical trials with a EudraCT protocol, of which   7007   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2018-001171-20
    Sponsor's Protocol Code Number:CB8025-31735
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2019-01-18
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2018-001171-20
    A.3Full title of the trial
    A 52-week, placebo-controlled, randomized, Phase 3 study to evaluate the safety and efficacy of seladelpar in subjects with primary biliary cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA).
    Estudio de fase 3, aleatorizado, controlado con placebo, de 52 semanas de duración, para evaluar la seguridad y la eficacia de seladelpar en sujetos con colangitis biliar primaria (CBP) y una respuesta insuficiente o intolerancia al ácido ursodesoxicólico (AUDC).
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A clinical trial to assess the safety and efficacy of seladelpar in patients with primary biliary cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA).
    Ensayo clínico para evaluar la seguridad y la eficacia de seladelpar en pacientes con colangitis biliar primaria (CBP) y una respuesta insuficiente o intolerancia al ácido ursodesoxicólico (AUDC).
    A.4.1Sponsor's protocol code numberCB8025-31735
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT03602560
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorCymaBay Therapeutics, Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportCymaBay Therapeutics, Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationCymaBay Therapeutics, Inc.
    B.5.2Functional name of contact pointSenior VP, RA&QA - Klara Dickinson
    B.5.3 Address:
    B.5.3.1Street Address7575 Gateway Boulevard Suite 110
    B.5.3.2Town/ cityNewark
    B.5.3.3Post code94560
    B.5.3.4CountryUnited States
    B.5.4Telephone number900834223
    B.5.6E-mailRegistroEspanolDeEstudiosClinicos@druginfo.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU3/17/1930
    D.3 Description of the IMP
    D.3.1Product nameSeladelpar
    D.3.2Product code MBX-8025
    D.3.4Pharmaceutical form Capsule
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNSELADELPAR
    D.3.9.1CAS number 928821-40-3
    D.3.9.4EV Substance CodeSUB192392
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameSeladelpar
    D.3.2Product code MBX-8025
    D.3.4Pharmaceutical form Capsule
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNSELADELPAR
    D.3.9.1CAS number 928821-40-3
    D.3.9.4EV Substance CodeSUB192392
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboCapsule
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Primary biliary cholangitis (PBC, formerly known as primary biliary cirrhosis) is a serious and potentially life threatening autoimmune disease of the liver characterized by impaired bile flow (cholestasis) and accumulation of toxic bile acids (BA).
    La colangitis biliar primaria (CBP, antes conocida como cirrosis biliar primaria) es una enfermedad autoinmune seria y potencialmente mortal para el hígado caracterizada por un deterioro del flujo biliar (colestasis) y acumulación de ácidos biliares tóxicos (BA).
    E.1.1.1Medical condition in easily understood language
    Disease of the liver
    Enfermedad del hígado
    E.1.1.2Therapeutic area Diseases [C] - Digestive System Diseases [C06]
    MedDRA Classification
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Evaluate the safety and effect on cholestasis of two seladelpar regimens (5 mg/day titrated to 10 mg/day and 10 mg/day) over 52 weeks of treatment compared to placebo.
    Evaluar la seguridad y el efecto sobre la colestasis de dos pautas de seladelpar (5 mg/día con ajuste a 10 mg/día y 10 mg/día) durante 52 semanas de tratamiento en comparación con placebo.
    E.2.2Secondary objectives of the trial
    Evaluate the effect of seladelpar on normalization of alkaline phosphate (AP) levels and to evaluate the effect of seladelpar on pruritus.
    Evaluate the effect of seladelpar on quality of life (QoL), to evaluate the effect of seladelpar on other measures of cholestasis, metabolic outcomes, PBC prognosis criteria, and the effect of seladelpar on PBC clinical outcomes.
    Evaluar el efecto de seladelpar sobre la normalización de las concentraciones de fosfatasa alcalina (FA) y evaluar el efecto de seladelpar sobre el prurito.
    Evaluar el efecto de seladelpar sobre la calidad de vida, evaluar el efecto de seladelpar sobre otras medidas de la colestasis, variables metabólicas y criterios pronósticos de la CBP, y el efecto de seladelpar sobre variables clínicas de la CBP.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Must have given written informed consent (signed and dated) and any authorizations required by local law
    2. 18 to 75 years old (inclusive)
    3. Male or female with a diagnosis of PBC, by at least two of the following criteria:
    • History of AP above ULN for at least 6 months
    • Positive anti-mitochondrial antibody (AMA) titers (>1/40 on immunofluorescence or M2 positive by enzyme linked immunosorbent assay [ELISA]) or positive PBC-specific antinuclear antibodies
    • Documented liver biopsy result consistent with PBC
    4. On a stable and recommended dose of UDCA for the past 12 months
    5. AP ≥ 1.67 × ULN
    6. Females of reproductive potential must use at least one barrier contraceptive and a second effective birth control method during the study and for at least 90 days after the last dose. Male subjects who are sexually active with female partners of reproductive potential must use barrier contraception and their female partners must use a second effective birth control method during the study and for at least 90 days after the last dose
    1. Haber otorgado el consentimiento informado por escrito (firmado y fechado) y las autorizaciones exigidas por la legislación local.
    2. Edad comprendida entre los 18 y 75 años, ambos inclusive.
    3. Varón o mujer con un diagnóstico de CBP, según dos o más de los criterios siguientes:
    • Antecedentes de FA por encima del LSN durante al menos seis meses.
    • Títulos positivos de anticuerpos antimitocondriales (AMA) (> 1/40 con inmunofluorescencia o M2 positivos mediante enzimoinmunoanálisis de adsorción [ELISA]) o anticuerpos antinucleares positivos específicos de la CBP.
    • Resultado documentado de la biopsia hepática compatible con CBP.
    4. Tratamiento con una dosis estable y recomendada de AUDC durante los últimos doce meses.
    5. FA ≥ 1,67 veces el LSN.
    6. Las mujeres en edad fértil deberán utilizar al menos un anticonceptivo de barrera y un segundo método anticonceptivo eficaz durante el estudio y hasta, como mínimo, 90 días después de la última dosis. Los varones que mantengan relaciones sexuales con parejas en edad fértil deberán utilizar un método anticonceptivo de barrera y sus parejas, un segundo método anticonceptivo eficaz durante el estudio y hasta, como mínimo, 90 días después de la última dosis.
    E.4Principal exclusion criteria
    1. Previous exposure to seladelpar (MBX-8025)
    2. A medical condition, other than PBC, that in the investigator’s opinion would preclude full participation in the study or confound its results (e.g., cancer)
    3. AST above 3 × ULN
    4. ALT above 3 × ULN
    5. Total bilirubin above 2.0 × ULN
    6. Advanced PBC as defined by the Rotterdam criteria (albumin below LLN AND total bilirubin above 1 × ULN
    7. Creatine kinase (CK) above 1.0 × ULN
    8. eGFR below 60 mL/min/1.73 m2 (calculated by MDRD formula)
    7. Serum creatinine above 1.0 × ULN
    9. International normalized ratio (INR) above 1.0 × ULN
    10. Platelet count below 100 × 103/µL
    11. Presence of clinically significant hepatic decompensation, including:
    - History of liver transplantation, current placement on liver transplantation list, or current Model for End-Stage Liver Disease (MELD) score ≥ 15
    - Complications of portal hypertension, including known esophageal varices, history of variceal bleeds or related interventions (e.g., transjugular intrahepatic portosystemic shunt placement), relevant ascites, hepatic encephalopathy
    - Cirrhosis with complications, including history or presence of spontaneous bacterial peritonitis
    12. Other chronic liver diseases:
    a.Current features of auto-immune hepatitis as determined by the investigator based on immunoserology, liver biochemistry and histology
    b.Primary sclerosing cholangitis determined by presence of diagnostic cholangiographic findings
    c.History or clinical evidence of alcoholic liver disease
    d.History or clinical evidence of alpha-1-antitrypsin deficiency
    e.Biopsy confirmed nonalcoholic steatohepatitis
    f.History or evidence of Gilbert’ Syndrome with elevated total bilirubin
    g.History or evidence of hemochromatosis
    h.Hepatitis B defined as presence of hepatitis B surface antigen (HBsAg)
    i.Hepatitis C defined as presence of HCV RNA
    13. Known history of HIV
    14. Evidence of significant alcohol consumption
    15. Evidence of drug abuse
    16. Subjects with inadequate response to obeticholic acid (OCA) or intolerance to OCA: OCA must be discontinued 30 days prior to Screening
    17. Use of colchicine, methotrexate, azathioprine, or long-term systemic corticosteroids (> 2 weeks) within two months prior to Screening
    18. Use of fibrates within 30 days prior to Screening
    19. Use of simvastatin within 7 days prior to Screening
    20. Use of an experimental or unapproved treatment for PBC within 30 days prior to Screening
    21. Use of experimental or unapproved immunosuppressant within 30 days prior to Screening
    22. Treatment with any other investigational therapy or device within 30 days or within five half-lives, whatever is longer, prior to Screening
    23. For females, pregnancy or breast-feeding
    24. Any other condition(s) that would compromise the safety of the subject or compromise the quality of the clinical study, as judged by the investigator.
    1. Exposición previa a seladelpar (MBX-8025).
    2. Enfermedad distinta de la CBP que, en opinión del investigador, impediría la participación plena en el estudio o confundiría sus resultados (p. ej., cáncer).
    3. AST > 3 veces el LSN.
    4. ALT > 3 veces el LSN.
    5. Bilirrubina total > 2,0 veces el LSN.
    6. CBP avanzada según los criterios de Róterdam (albúmina < LIN Y bilirrubina total > 1,0 veces el LSN).
    7. Creatina cinasa (CK) > 1,0 veces el LSN.
    8. FGe < 60 ml/min/1,73 m2 (calculada mediante la fórmula MDRD).
    9. Cociente internacional normalizado (INR) > 1,0 veces el LSN.
    10. Recuento de plaquetas < 100 x 103/μl.
    11. Presencia de descompensación hepática clínicamente significativa, como:
    - Antecedentes de trasplante hepático, inclusión actual en lista de espera de trasplante hepático o puntuación MELD actual ≥ 15
    - Complicaciones de la hipertensión portal, como varices esofágicas conocidas, antecedentes de varices hemorrágicas o intervenciones relacionadas (por ejemplo, colocación de una derivación portosistémica intrahepática transyugular), ascitis importante o encefalopatía hepática.
    - Cirrosis con complicaciones, como antecedentes o presencia de peritonitis bacteriana espontánea.
    12. Otras hepatopatías crónicas:
    a. Características actuales de hepatitis autoinmunitaria, determinada por el investigador basándose en la inmunoserología, la bioquímica hepática y la histología.
    b. Colangitis esclerosante primaria, determinada por la presencia de signos colangiográficos diagnósticos.
    c. Antecedentes o signos clínicos de hepatopatía alcohólica.
    d. Antecedentes o signos clínicos de carencia de α-1-antitripsina.
    e. Esteatohepatitis no alcohólica confirmada mediante biopsia.
    f. Antecedentes o signos de síndrome de Gilbert con elevación de la bilirrubina total.
    g. Antecedentes o signos de hemocromatosis.
    h. Hepatitis B, definida como la presencia del antígeno de superficie del virus de la hepatitis B (HBsAg).
    i. Hepatitis C, definida como la presencia de ARN del VHC.
    13. Antecedentes de infección por el VIH.
    14. Datos de consumo importante de alcohol.
    15. Datos de drogadicción.
    16. Sujetos con respuesta insuficiente o intolerancia al ácido obeticólico (AOC): el AOC deberá suspenderse 30 días antes de la selección.
    17. Uso de colchicina, metotrexato, azatioprina o corticosteroides sistémicos a largo plazo (> 2 semanas) en los dos meses previos a la selección.
    18. Uso de fibratos en los 30 días previos a la selección.
    19. Uso de simvastatina en los 7 días previos a la selección.
    20. Uso de un tratamiento experimental o no aprobado para la CBP en los 30 días previos a la selección.
    21. Uso de inmunodepresores experimentales o no aprobados en los 30 días previos a la selección.
    22. Tratamiento con cualquier otro fármaco o dispositivo en investigación en los 30 días previos a la selección o el período equivalente a cinco semividas, lo que suponga más tiempo.
    23. En las mujeres, embarazo o lactancia.
    24. Cualquier otra enfermedad que pueda comprometer la seguridad del sujeto o la calidad del estudio clínico, según el criterio del investigador.
    E.5 End points
    E.5.1Primary end point(s)
    1 - Response on the composite endpoint of AP and total bilirubin at 12 months:
    o AP < 1.67 × ULN,
    o ≥ 15% decrease in AP, and
    o Total bilirubin ≤ ULN
    2 - Assessment of treatment-emergent AEs (TEAEs) (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] Version 4.0), biochemistry and hematology
    1 - Respuesta en el criterio de valoración compuesto de FA y bilirrubina total a los 12 meses:
    ○ FA < 1,67 veces el límite superior de la normalidad (LSN),
    ○ Disminución ≥ 15 % de la FA y
    ○ Bilirrubina total ≤ LSN.
    2 - Evaluación de los AA surgidos durante el tratamiento (AAST) (Criterios terminológicos comunes para acontecimientos adversos [CTCAE] del National Cancer Institute [NCI], versión 4.0), la bioquímica y la hematología
    E.5.1.1Timepoint(s) of evaluation of this end point
    1- 12 months
    2 - Throughout the study
    1- 12 meses
    2 - A lo largo del estudio
    E.5.2Secondary end point(s)
    1 - Proportion of patients with AP ≤1.0 × ULN at 12 months
    2 - Change from baseline in pruritus NRS at 6 months
    1 - Proporción de sujetos con FA ≤ 1,0 veces el LSN a los 12 meses.
    2 - Variación del prurito entre el momento basal y los 6 meses
    E.5.2.1Timepoint(s) of evaluation of this end point
    1 - 12 months
    2 - 6 months
    1- 12 meses
    2 - A lo largo del estudio
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned10
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA70
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Austria
    Belgium
    Brazil
    Canada
    France
    Germany
    Greece
    Hungary
    Israel
    Italy
    Korea, Republic of
    Mexico
    Netherlands
    Poland
    Romania
    Russian Federation
    Serbia
    Spain
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    At the end of 52 weeks of treatment, subjects will be invited to participate in the long-term study (CB8025-31731) and continue their treatment with seladelpar; subjects on placebo will be switched to seladelpar. Subjects who do not want to continue seladelpar treatment beyond 52 weeks and decline long-term study participation will have a follow-up visit performed 4 weeks after the last dose of the study drug.
    Al final de las 52 semanas de tratamiento, los sujetos serán invitados a participar en el estudio a largo plazo (CB8025-31731) y continuarán su tratamiento con seladelpar; los sujetos con placebo serán cambiados a seladelpar. Los sujetos que no deseen continuar el tratamiento con seladelpar más allá de las 52 semanas y rechacen la participación en el estudio a largo plazo tendrán una visita de seguimiento realizada 4 semanas después de la última dosis del medicamento del estudio.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months10
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months3
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 200
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 40
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state25
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 146
    F.4.2.2In the whole clinical trial 240
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    At the end of 52 weeks of treatment, subjects will be invited to participate in the long-term study (CB8025-31731) and continue their treatment with seladelpar; subjects on placebo will be switched to seladelpar. Subjects who do not want to continue seladelpar treatment beyond 52 weeks and decline long-term study participation will have a follow-up visit performed 4 weeks after the last dose of the study drug.
    Al final de las 52 semanas de tratamiento, los sujetos serán invitados a participar en el estudio a largo plazo (CB8025-31731) y continuarán su tratamiento con seladelpar; los sujetos con placebo serán cambiados a seladelpar. Los sujetos que no deseen continuar el tratamiento con seladelpar más allá de las 52 semanas y rechacen la participación en el estudio a largo plazo tendrán una visita de seguimiento realizada 4 semanas después de la última dosis del medicamento del estudio.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2018-12-21
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2018-12-19
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    P.Date of the global end of the trial2019-12-20
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2022 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA